DDInter1140 DDInter740
Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortality; 90% of deaths from malaria occur in Africa. Individuals at the highest risk for malaria are those in disease naïve populations, children under age 5, refugees in Central and Eastern Africa, nonimmune civilian and military travelers, pregnant women, and immigrants traveling to their place of origin. Mefloquine, commonly known as Lariam, is an antimalarial drug used for the prevention and treatment of malaria caused by infection with Plasmodium vivax and Plasmodium falciparum. The drug was initially discovered by the Walter Reed Army Institute of Research (WRAIR) during a malaria drug discovery program between 196
Flecainide is a Class I anti-arrhythmic agent like [encainide] and [propafenone]. Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter.[L8878,L5056] Flecainide was granted FDA approval on 31 October 1985.
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Mefloquine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Flecainide
Mefloquine {u} (Compound) upregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is upregulated by {v} (Compound) Flecainide
Mefloquine {u} (Compound) causes {v} (Side Effect) Shock
Shock {u} (Side Effect) is caused by {v} (Compound) Flecainide
Mefloquine {u} (Compound) upregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is regulated by {v} (Gene) PHGDH
PHGDH {u} (Gene) is upregulated by {v} (Compound) Flecainide
Mefloquine {u} may lead to a major life threatening interaction when taken with {v} Clozapine
Clozapine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Flecainide
Mefloquine {u} (Compound) upregulates {v} (Gene) PHGDH
PHGDH {u} (Gene) regulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is upregulated by {v} (Compound) Flecainide
Mefloquine {u} (Compound) upregulates {v} (Gene) DDIT4
DDIT4 {u} (Gene) is regulated by {v} (Gene) SHB
SHB {u} (Gene) is downregulated by {v} (Compound) Flecainide
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluoxetine
Fluoxetine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Flecainide
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluoxetine
Fluoxetine {u} (Compound) downregulates {v} (Gene) EIF4EBP1
EIF4EBP1 {u} (Gene) is upregulated by {v} (Compound) Flecainide
Mefloquine (Compound) resembles Flecainide (Compound)
Mefloquine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Flecainide (Compound)
Mefloquine (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Flecainide (Compound)
Mefloquine (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Flecainide (Compound)
Mefloquine (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is regulated by PHGDH (Gene) and PHGDH (Gene) is upregulated by Flecainide (Compound)
Mefloquine may lead to a major life threatening interaction when taken with Clozapine and Clozapine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Flecainide (Compound)
Mefloquine (Compound) upregulates PHGDH (Gene) and PHGDH (Gene) regulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Flecainide (Compound)
Mefloquine (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is regulated by SHB (Gene) and SHB (Gene) is downregulated by Flecainide (Compound)
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Fluoxetine and Fluoxetine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Flecainide (Compound)
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Fluoxetine and Fluoxetine (Compound) downregulates EIF4EBP1 (Gene) and EIF4EBP1 (Gene) is upregulated by Flecainide (Compound)